毕得医药
(688073)
| 流通市值：54.13亿 | | | 总市值：54.13亿 |
| 流通股本：9088.29万 | | | 总股本：9088.29万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 323,276,733.74 | 1,323,810,726.7 | 979,111,093.03 | 627,526,589.12 |
| 营业收入 | 323,276,733.74 | 1,323,810,726.7 | 979,111,093.03 | 627,526,589.12 |
| 二、营业总成本 | 262,853,915.44 | 1,107,810,422.06 | 809,767,058.8 | 522,427,598.32 |
| 营业成本 | 165,248,354.14 | 734,238,643.78 | 543,920,142.3 | 349,840,486.76 |
| 税金及附加 | 1,095,770.37 | 5,503,022.81 | 4,204,981.84 | 3,402,777.89 |
| 销售费用 | 35,239,041.36 | 150,394,336.32 | 108,201,023.44 | 68,419,157.93 |
| 管理费用 | 33,618,012.56 | 140,296,473.27 | 100,307,661.83 | 66,590,352.85 |
| 研发费用 | 14,988,972.72 | 62,715,609.01 | 46,034,736.98 | 29,996,679.58 |
| 财务费用 | 12,663,764.29 | 14,662,336.87 | 7,098,512.41 | 4,178,143.31 |
| 其中:利息费用 | 1,097,266.76 | 5,801,324.09 | 4,623,861.27 | 3,572,514.02 |
| 其中:利息收入 | 3,788,795.59 | 11,358,501.38 | 7,202,904.35 | 3,379,806.55 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 610,095.9 | 2,599,122.99 | 755,794.37 | 742,557.99 |
| 加:投资收益 | 404,071.08 | 7,983,317.65 | 7,186,232.16 | 6,707,093.94 |
| 资产处置收益 | 4,877,893.13 | 3,898,219.62 | 3,803,522 | 330,567.88 |
| 资产减值损失(新) | -8,175,314.71 | -41,022,275.45 | -27,613,661.75 | -18,647,601.9 |
| 信用减值损失(新) | -749,108.14 | -3,948,628.78 | -3,766,888.42 | -3,269,405.25 |
| 其他收益 | 4,305,425.12 | 10,988,043.25 | 10,075,485.25 | 9,676,844.1 |
| 四、营业利润 | 61,695,880.68 | 196,498,103.92 | 159,784,517.84 | 100,639,047.56 |
| 加:营业外收入 | 259,787.39 | 1,276,258.18 | 603,510.53 | 507,544.91 |
| 减:营业外支出 | 575,736.04 | 2,346,878.68 | 821,563.15 | 302,765.56 |
| 五、利润总额 | 61,379,932.03 | 195,427,483.42 | 159,566,465.22 | 100,843,826.91 |
| 减:所得税费用 | 14,550,791.63 | 43,687,831.83 | 39,832,448.81 | 27,437,767.37 |
| 六、净利润 | 46,829,140.4 | 151,739,651.59 | 119,734,016.41 | 73,406,059.54 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 46,829,140.4 | 151,739,651.59 | 119,734,016.41 | 73,406,059.54 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 46,829,140.4 | 151,739,651.59 | 119,734,016.41 | 73,406,059.54 |
| 扣除非经常损益后的净利润 | 39,924,621.68 | 132,315,476.46 | 102,459,077.7 | 59,163,606.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.54 | 1.75 | 1.37 | 0.84 |
| (二)稀释每股收益 | 0.54 | 1.73 | 1.37 | 0.84 |
| 八、其他综合收益 | 3,042,449.36 | 6,977,647.18 | 1,945,985.63 | 2,453,798.93 |
| 归属于母公司股东的其他综合收益 | 3,042,449.36 | 6,977,647.18 | 1,945,985.63 | 2,453,798.93 |
| 九、综合收益总额 | 49,871,589.76 | 158,717,298.77 | 121,680,002.04 | 75,859,858.47 |
| 归属于母公司股东的综合收益总额 | 49,871,589.76 | 158,717,298.77 | 121,680,002.04 | 75,859,858.47 |
| 公告日期 | 2026-04-30 | 2026-04-23 | 2025-10-30 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |